The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has voted to expand the use of RSV vaccines to a key group of adults at high risk of severe respiratory illness. Starting at age 50, these individuals are recommended to receive a single dose of the vaccine. The move provides a boost to manufacturers whose sales fell sharply last year due to decreased demand for the vaccine. RSV usually causes mild symptoms but can be life-threatening to older adults with weakened immune systems.
Source: https://www.bloomberg.com/news/articles/2025-04-16/cdc-panel-votes-to-expand-rsv-vaccine-use-in-older-adults